Lexicon Pharmaceuticals, Inc.


Industry / private company

Location:
The Woodlands, TX, United States (USA)


Publications in cooperation with FAU scientists


Anthony, L., Kulke, M., Caplin, M., Bergsland, E., Oberg, K., Pavel, M.E.,... Jiang, W. (2019). Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials. In PANCREAS (pp. 428-428). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Hoersch, D., Kulke, M.H., Caplin, M.E., Anthony, L.B., Bergsland, E., Oberg, K.,... Pavel, M.E. (2018). Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period. (pp. 341-342).
Lapuerta, P., Kulke, M.H., Pavel, M.E., Biran, T., Fleming, R., Zacks, J.S.,... Warner, R.R.P. (2018). Integrated Safety Analysis of Telotristat Ethyl in Patients With Carcinoid Heart Disease. (pp. 345-345).
Pavel, M.E., Gross, D.J., Benavent, M., Perros, P., Srirajaskanthan, R., Warner, R.R.P.,... Garcia-Carbonero, R. (2018). Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocrine-Related Cancer, 25(3), 309-322. https://dx.doi.org/10.1530/ERC-17-0455
Pavel, M., Benavent, M., Perros, P., Srirajaskanthan, R., Warner, R.R.P., Kulke, M.H.,... Gross, D.J. (2018). Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial. (pp. 350-350).
Dillon, J., Kulke, M., Warner, R., Bergsland, E., Welin, S., O'Dorisio, T.,... Pavel, M.E. (2018). Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome. (pp. 224-224).
Dillon, J.S., Kulke, M.H., Pavel, M.E., Horsch, D., Anthony, L.B., Warner, R.R.P.,... Lapuerta, P. (2018). Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study. (pp. 337-338).
Weickert, M.O., Kaltsas, G., Hoersch, D., Lapuerta, P., Pavel, M.E., Valle, J.W.,... Kulke, M.H. (2018). Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. (pp. 357-358).
Pavel, M.E., Gable, J., Kulke, M.H., Bergsland, E., Anthony, L.B., Caplin, M.E.,... Hudgens, S. (2017). Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome. (pp. 238-238).
Beyer, C., Huang, J., Beer, J., Zhang, Y., Palumbo-Zerr, K., Zerr, P.,... Munoz Becerra, L.E. (2015). Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the Rheumatic Diseases, 74(6), 1317-24. https://dx.doi.org/10.1136/annrheumdis-2013-204401

Last updated on 2017-16-05 at 06:48